Abstract：Objective To investigate the resistance of Mycobacterium tuberculosis to first-line anti-tuberculosis drugs in Jiaxing City, Zhejiang Province from 2017 to 2019, so as to provide insights into improvements of the therapeutic effect of pulmonary tuberculosis. Methods Data pertaining to pulmonary tuberculosis in Jiaxing City from 2017 to 2019 were collected from the Tuberculosis Surveillance System of Chinese Disease Prevention and Control Information System, including demographics, treatment classification, sputum culture and drug resistance. The spectrum, types and prevalence of drug resistance in M. tuberculosis to four first-line tuberculosis drugs, including isoniazid (INH), rifampicin (RFP), streptomycin (SM) and ethambutol (EMB), was analyzed using a descriptive epidemiological method. Results A total of 1 310 M. tuberculosis isolates were cultured from pulmonary tuberculosis patients in Jiaxing City from 2017 to 2019, and there were 259 M. tuberculosis isolates that were resistant to anti-tuberculosis drugs, with an overall drug resistance rate of 19.77%. The prevalence rates of drug resistance to INH, SM, RFP and EMB were 13.36%, 11.83%, 5.50% and 3.59%, respectively. The prevalence of drug resistance was lower in M. tuberculosis isolates from treatment-naïve patients than from retreated patients (18.45% vs. 34.58%, P<0.05). M. tuberculosis isolates presented high resistance to SM (4.50%) and INH alone (4.35%), the highest resistance to INH-SM combinations (3.28%), and the highest resistance to INH+RFP+SM combinations (1.83%). Sixteen isolates were resistant to all the four drugs, with a drug resistance rate of 1.22%. The proportions of resistance to a single drug, RFP resistance, multidrug resistance and resistance to two and more drugs were 10.31%, 5.50%, 4.73% and 4.73%, respectively. In addition, the prevalence of RFP resistance among all patients and treatment-naïve patients both showed a tendency towards a rise from 2017 to 2019 (P<0.05). The prevalence of RFP resistance (7.01% vs. 3.76%) and resistance to two and more drugs (6.01% vs. 3.25%) was both higher among interprovincial mobile tuberculosis patients than among local non-mobile patients (P<0.05). Conclusions The overall prevalence of drug resistance was lower in M. tuberculosis isolates in Jiaxing City from 2017 to 2019 than in Zhejiang Province, with INH and RFP resistance as predominant types.
王远航, 胡洁, 葛锐, 富小飞, 亓云鹏. 嘉兴市结核分枝杆菌耐药情况分析[J]. 预防医学, 2023, 35(8): 705-709.
WANG Yuanhang, HU Jie, GE Rui, FU Xiaofei, QI Yunpeng. Drug resistance surveillance in Mycobacterium tuberculosis in Jiaxing City. Preventive Medicine, 2023, 35(8): 705-709.
[1] JEREMIAH C,ESKILD P,REBECCA N,et al.The WHO global tuberculosis 2021 report—not so good news and turning the tide back to end TB[J].Int J Infect,2022,124(Suppl.1):26-29. [2] 唐神结,肖和平.抗结核药物研究进展[J].中华全科医师杂志,2011,11(10):814-816. [3] World Health Organization.Global tuberculosis report 2022[R].Geneva:WHO,2022. [4] LI B Y,SHI W P,ZHOU C M,et al.Rising challenge of multidrug-resistant tuberculosis in China:a predictive study using Markov modeling[J].Infect Dis Poverty,2020,9(3):57-64. [5] 吴亦斐,赵刚,陈淑丹,等.肺结核原体和易感因素及结核分枝杆菌优势耐药谱分析[J].中国人兽共患病学报,2019,35(6):480-486. [6] 刘剑君,赵雁林,陈明亭,等.中国结核病防治工作技术指南[M].北京:人民卫生出版社,2021. [7] 中国防痨协会.耐药结核病化学治疗指南(2019年简版)[J].中国防痨杂志,2019,41(10):1025-1073. [8] 赵雁林,逄宇.结核病实验室检验规程[M].北京:人民卫生出版社,2015. [9] 陈松华,吴蓓蓓,柳正卫,等.浙江省结核病耐药状况分析[J].预防医学,2016,28(8):757-765. [10] LI Q,ZHAO G,WU L,et al.Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou,China[J/OL].Antimicrob Resist Infect Control,2018,7[2023-07-27].https://doi.org/10.1186/s13756-018-0348-7. [11] 汪敏,李静,张阳奕,等.2013—2017年上海市结核病耐药状况及影响因素分析[J].中国防痨杂志,2019,41(12):1269-1276. [12] 叶慧,缭星国,宋启发,等.温州市利福平耐药肺结核流行病学特征(2015—2020年)[J].国际流行病学传染病学杂志,2022,49(5):320-324. [13] 崔彩岩,高凡,白尧,等.2011—2020年西安市肺结核流行趋势的Joinpoint回归分析[J].职业与健康,2022,38(5):649-653. [14] 韩志英,李静,孙果梅,等.上海市静安区2010—2014年结核杆菌耐药状况及传播特征研究[J].中国预防医学杂志,2017,18(9):680-684.
